Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283165966> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4283165966 endingPage "A570" @default.
- W4283165966 startingPage "A570" @default.
- W4283165966 abstract "TYPE: Late Breaking Abstract TOPIC: Lung Cancer INTRODUCTION: Lung cancer (LC) is the leading cause of cancer-related death worldwide and it is responsible for nearly 50% of brain metastasis (BM) cases. Afatinib is a second-generation irreversible EGFR tyrosine kinase inhibitor, indicated in the treatment of metastatic LC with activating EGFR mutations. CASE PRESENTATION: A 71-year-old woman, ECOG PS 1, was diagnosed with stage IVb LC (T3N0M1b), EGFR mutated (exon 18: Glu790Lys, Lys744Asn, Gly719Ser). Staging brain MRI showed 2 left brain lesions, suggestive of BM, not surgically approachable: one in the parietal region (20x16mm) and another (3mm) in the temporo-occipital transition. In the Multidisciplinary Tumor Board was decided treatment with afatinib and stereotactic brain surgery (SBS). To plan SBS another brain MRI was performed showing a significant reduction of the left parietal lesion (10x8mm; figure 1) and complete disappearance of the other lesion, after 8 days of treatment, and SBS was canceled. Reevaluation after 3 months revealed partial imaging response on the lung and brain (BM with 9mm, major axis). Due to grade 2-3 skin rash and paronychia, the treatment dose was reduced until 20mg/day, with good tolerance. DISCUSSION: Despite having incomplete blood-brain barrier penetration, afatinib has the potential to treat LC BM, with a reported intracranial response rate ranging from 35%-72.9%. This efficacy was demonstrated in this case report, allowing brain radiation sparing strategy. CONCLUSIONS: This case report shows the effectiveness of afatinib in BM from EGFR mutated lung adenocarcinoma. DISCLOSURE: No significant relationships. KEYWORD: Brain metastases" @default.
- W4283165966 created "2022-06-21" @default.
- W4283165966 creator A5031588240 @default.
- W4283165966 creator A5031651628 @default.
- W4283165966 creator A5047521453 @default.
- W4283165966 creator A5071300812 @default.
- W4283165966 creator A5081940702 @default.
- W4283165966 date "2022-06-01" @default.
- W4283165966 modified "2023-09-26" @default.
- W4283165966 title "LUNG CANCER METASTASES IN THE BRAIN: MAJOR RESPONSE WITH AFATINIB" @default.
- W4283165966 doi "https://doi.org/10.1016/j.chest.2022.04.104" @default.
- W4283165966 hasPublicationYear "2022" @default.
- W4283165966 type Work @default.
- W4283165966 citedByCount "1" @default.
- W4283165966 countsByYear W42831659662022 @default.
- W4283165966 crossrefType "journal-article" @default.
- W4283165966 hasAuthorship W4283165966A5031588240 @default.
- W4283165966 hasAuthorship W4283165966A5031651628 @default.
- W4283165966 hasAuthorship W4283165966A5047521453 @default.
- W4283165966 hasAuthorship W4283165966A5071300812 @default.
- W4283165966 hasAuthorship W4283165966A5081940702 @default.
- W4283165966 hasBestOaLocation W42831659661 @default.
- W4283165966 hasConcept C121608353 @default.
- W4283165966 hasConcept C126322002 @default.
- W4283165966 hasConcept C142724271 @default.
- W4283165966 hasConcept C143998085 @default.
- W4283165966 hasConcept C2776256026 @default.
- W4283165966 hasConcept C2777714996 @default.
- W4283165966 hasConcept C2778087573 @default.
- W4283165966 hasConcept C2778164965 @default.
- W4283165966 hasConcept C2779013556 @default.
- W4283165966 hasConcept C2779438470 @default.
- W4283165966 hasConcept C2780387249 @default.
- W4283165966 hasConcept C2780580887 @default.
- W4283165966 hasConcept C2780586478 @default.
- W4283165966 hasConcept C2781182431 @default.
- W4283165966 hasConcept C509974204 @default.
- W4283165966 hasConcept C71924100 @default.
- W4283165966 hasConceptScore W4283165966C121608353 @default.
- W4283165966 hasConceptScore W4283165966C126322002 @default.
- W4283165966 hasConceptScore W4283165966C142724271 @default.
- W4283165966 hasConceptScore W4283165966C143998085 @default.
- W4283165966 hasConceptScore W4283165966C2776256026 @default.
- W4283165966 hasConceptScore W4283165966C2777714996 @default.
- W4283165966 hasConceptScore W4283165966C2778087573 @default.
- W4283165966 hasConceptScore W4283165966C2778164965 @default.
- W4283165966 hasConceptScore W4283165966C2779013556 @default.
- W4283165966 hasConceptScore W4283165966C2779438470 @default.
- W4283165966 hasConceptScore W4283165966C2780387249 @default.
- W4283165966 hasConceptScore W4283165966C2780580887 @default.
- W4283165966 hasConceptScore W4283165966C2780586478 @default.
- W4283165966 hasConceptScore W4283165966C2781182431 @default.
- W4283165966 hasConceptScore W4283165966C509974204 @default.
- W4283165966 hasConceptScore W4283165966C71924100 @default.
- W4283165966 hasIssue "6" @default.
- W4283165966 hasLocation W42831659661 @default.
- W4283165966 hasOpenAccess W4283165966 @default.
- W4283165966 hasPrimaryLocation W42831659661 @default.
- W4283165966 hasRelatedWork W150263754 @default.
- W4283165966 hasRelatedWork W1602357875 @default.
- W4283165966 hasRelatedWork W2289253999 @default.
- W4283165966 hasRelatedWork W2335218895 @default.
- W4283165966 hasRelatedWork W2734557114 @default.
- W4283165966 hasRelatedWork W2888534976 @default.
- W4283165966 hasRelatedWork W2906574801 @default.
- W4283165966 hasRelatedWork W2968621343 @default.
- W4283165966 hasRelatedWork W2981576059 @default.
- W4283165966 hasRelatedWork W4200546557 @default.
- W4283165966 hasVolume "161" @default.
- W4283165966 isParatext "false" @default.
- W4283165966 isRetracted "false" @default.
- W4283165966 workType "article" @default.